Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thioridazine
Drug ID BADD_D02200
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status approved; withdrawn
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00373
MeSH ID D013881
PubChem ID 5452
TTD Drug ID D0U1OE
NDC Product Code Not Available
UNII N3D6TG58NI
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H26N2S2
CAS Registry Number 50-52-2
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphagia07.01.06.003--
Dystonia17.01.03.001---
Ejaculation failure21.03.01.003---
Eosinophilia01.02.04.001--
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.001---
Extrapyramidal disorder17.01.02.007--
Feeling abnormal08.01.09.014---
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.016--
Galactorrhoea05.03.04.002; 21.05.02.002---
Gynaecomastia05.05.02.003; 21.05.04.003--
Hallucination19.10.04.003--
Headache17.14.01.001--
Heart rate irregular13.14.04.003---
Hepatotoxicity09.01.07.009; 12.03.01.008---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkinesia17.01.02.008---
Hyperpyrexia08.05.02.002---
Hypersensitivity10.01.03.003--
Hypertonia15.05.04.007; 17.05.02.001---
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001---
Incontinence07.01.06.011; 17.05.01.006; 20.02.02.004---
Insomnia17.15.03.002; 19.02.01.002--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.005--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukopenia01.02.02.001---
Loss of consciousness17.02.04.004---
Menstruation irregular05.05.01.008; 21.01.01.005--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene